NCT07033143

Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC Gastric Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Although the immunotherapy combination regimen has shown good data and safety during the perioperative period of gastric cancer, more clinical studies are still needed to explore the treatment regimens, the number of treatment cycles, the screening of beneficiary populations, and the safety assessment of different drug combinations of immunotherapy combination therapy as adjuvant treatment after gastric cancer surgery.

Detailed description

Although the immunotherapy combination regimen has shown good data and safety during the perioperative period of gastric cancer, more clinical studies are still needed to explore the treatment regimens, the number of treatment cycles, the screening of beneficiary populations, and the safety assessment of different drug combinations of immunotherapy combination therapy as adjuvant treatment after gastric cancer surgery.

Conditions

• Gastric Cance

Interventions

Type	Name	Description
DRUG	Adebrelimab+SOX	Adebrelimab: 1200mg, intravenous drip, day 1, 21 days as one cycle, treatment duration is 1 year. SOX: Eight cycles after the operation, intravenous infusion of oxaliplatin at 130 mg/m2. On the first day, oral administration of S-1 at 40-60 mg twice a day. From the first to the 14th day, 21 days constitute one cycle. Enhanced CT examinations of the chest, abdomen and pelvis were conducted every 9-12 weeks in the first year of treatment. Then have a check-up every 24 weeks.

Timeline

• Start date: 2025-07-01
• Primary completion: 2028-07-01
• Completion: 2029-07-01
• First posted: 2025-06-24
• Last updated: 2025-06-24